Lantheus Holdings (NASDAQ:LNTH) Stock, Quote.Headers.trade-ideas

Lantheus Holdings

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

investor charts ai2

Equities

Federal Reserve

Markets

ETFs

FTAI

LNTH

Small-cap stocks, including Comfort Systems USA, Fabrinet, and Carvana, have rallied for 5 days, with iShares Russell 2000 ETF up 9% in 5 sessions.

Russell 2000 Marks Fifth Day Of Gains: What&#39;s Driving Surge In Small-Cap Stocks?

QuantumScape QS Stock

Mid Cap

News

Movers

General

APGE

CRNX

JOBY

KYMR

PLUG

SMMT

XPEV

10 mid-cap stocks jumped in last week, including QuantumScape, Lantheus Holdings, Sunrun, Kymera Therapeutics, Apogee Therapeutics, Joby Aviation, Crinetics Pharmaceuticals, Dyne Therapeutics, Summit Therapeutics, Plug Power and XPeng Inc.

XPeng &amp; QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

Russell,2000,Index.magnifying,Glass,Showing,The,Words.background,Of,Banknotes,And

Analyst Color

Broad U.S. Equity ETFs

Small Cap

EVGO

IGMS

MORF

OUST

PLSE

SOUN

The Russell 2000 index of small caps recorded its best weekly performance since October 2023, surging over 6%, driven by lower-than-expected June inflation data and potential interest rate cuts.

Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is &#39;Clouded By Fed&#39;s Concerns Over Labor Market,&#39; Analyst Warns

Lantheus Holdings Inc

<ul>
<li>Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival</li>
<li>Overall Response Rate was&nbsp;38.1%&nbsp;vs.&nbsp;12.0%&nbsp;for the ARPI switch arm, including&nbsp;9.3%&nbsp;Complete Responses</li>
<li>Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy&mdash;Prostate (FACT-P)</li>
<li>Interim Overall Survival Crossover Adjusted Hazard Ratio was &lt;1.00 when Assessed Using Two-Stage and Inverse Probability Censoring Weighting Methods</li>
<li>Overall Survival data continue to mature, an update is expected once data are available for&nbsp;75%&nbsp;of protocol-specified target OS events</li>
</ul>

Reported Sunday, Lantheus Unveils Phase 3 SPLASH Trial Results In PSMA-Positive Metastatic Prostate Cancer At ESMO 2024

Redburn Atlantic analyst Ed Ridley-Day initiates coverage on Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy rating and announces Price Target of $175.

Price Target

Initiation

Analyst Ratings

Redburn Atlantic Initiates Coverage On Lantheus Holdings with Buy Rating, Announces Price Target of $175

Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that Oliver Sartor, MD, Director of Radiopharmaceutical Trials and Professor of Medical Oncology at the&nbsp;Mayo Clinic&nbsp;in&nbsp;Rochester, Minnesota, will deliver an oral presentation, including additional clinical data from PNT2002's initial December 2023 readout, during the European Society of Medical Oncology (ESMO) Annual Meeting in Barcelona on Sunday, September 15, 2024. &nbsp;

Biotech

Lantheus To Present Additional Clinical Data From Phase 3 Pivotal SPLASH Trial In PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress In Barcelona On Sunday, September 15, 2024

JMP Securities analyst David Turkaly maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Market Outperform and lowers the price target from $130 to $125.

JMP Securities Maintains Market Outperform on Lantheus Holdings, Lowers Price Target to $125

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and lowers the price target from $141 to $135.

Truist Securities Maintains Buy on Lantheus Holdings, Lowers Price Target to $135

Whales with a lot of money to spend have taken a noticeably bullish stance on Lantheus Holdings.
Looking at options history for Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) we detected 9 trades.
If we consider the specifics of each trade, it is accurate to state that 55% of the investors opened trades with bullish expectations and 33% with bearish.
From the overall spotted trades, 6 are puts, for a total amount of $277,310 and 3, calls, for a total amount of $502,500.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $90.0 to $155.0 for Lantheus Holdings over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Lantheus Holdings's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Lantheus Holdings's significant trades, within a strike price range of $90.0 to $155.0, over the past month.
<h3>Lantheus Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1722441659_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.5</td>
<td>$20.5</td>
<td>$20.5</td>
<td>$90.00</td>
<td>$307.5K</td>
<td>1.2K</td>
<td style="text-align: right;">350</td>
</tr>
<tr>
<td>LNTH</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$21.4</td>
<td>$19.5</td>
<td>$19.5</td>
<td>$90.00</td>
<td>$156.0K</td>
<td>1.2K</td>
<td style="text-align: right;">100</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$20.5</td>
<td>$19.2</td>
<td>$19.2</td>
<td>$120.00</td>
<td>$67.2K</td>
<td>338</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$9.3</td>
<td>$7.4</td>
<td>$8.5</td>
<td>$110.00</td>
<td>$62.0K</td>
<td>960</td>
<td style="text-align: right;">77</td>
</tr>
<tr>
<td>LNTH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$60.5</td>
<td>$57.3</td>
<td>$57.3</td>
<td>$155.00</td>
<td>$57.3K</td>
<td>0</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Lantheus Holdings</h3>
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Following our analysis of the options activities associated with Lantheus Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Lantheus Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,250,895, with LNTH's price down by -16.19%, positioned at $92.0.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
<h3>What The Experts Say On Lantheus Holdings</h3>
Over the past month, 4 industry analysts have shared their insights on this stock, proposing an average target price of $137.75.
<ul>
<li>Maintaining their stance, an analyst from Leerink Partners continues to hold a Outperform rating for Lantheus Holdings, targeting a price of $127. </li>
<li>Consistent in their evaluation, an analyst from B. Riley Securities keeps a Buy rating on Lantheus Holdings with a target price of $146. </li>
<li>Maintaining their stance, an analyst from Jones Trading continues to hold a Buy rating for Lantheus Holdings, targeting a price of $137. </li>
<li>An analyst from Truist Securities has decided to maintain their Buy rating on Lantheus Holdings, which currently sits at a price target of $141. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lantheus Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Lantheus Holdings's Options Frenzy: What You Need to Know

WIIM

Lantheus shares are trading lower after the company cut its FY24 EPS outlook.

Full Year 2024 Financial Guidance
<table align="center" cellspacing="0" style="width:100%">
<tbody>
<tr>
<td style="text-align:center; vertical-align:bottom; width:33%">&nbsp;</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued July 31, 2024</td>
<td style="text-align:center; vertical-align:bottom; width:33%">Guidance Issued May 2, 2024</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Revenue</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
<td style="text-align:center; vertical-align:bottom">$1.50 billion - $1.52 billion</td>
</tr>
<tr>
<td style="vertical-align:bottom">FY 2024 Adjusted Fully Diluted EPS</td>
<td style="text-align:center; vertical-align:bottom">$6.60 - $6.70</td>
<td style="text-align:center; vertical-align:bottom">$7.00 - $7.20</td>
</tr>
</tbody>
</table>

Guidance

Lantheus Cuts FY24 Adj. EPS Outlook Form $7.00-$7.20 To $6.60-$6.70 Vs. $7.07 Estimate, Maintains Revenue Outlook Of $1.50B-$1.52B Vs. $1.51B Estimate

Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) reported quarterly earnings of $1.80 per share which missed the analyst consensus estimate of $1.83 by 1.64 percent. This is a 16.88 percent increase over earnings of $1.54 per share from the same period last year. The company reported quarterly sales of $394.091 million which beat the analyst consensus estimate of $382.153 million by 3.12 percent. This is a 22.50 percent increase over sales of $321.700 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Lantheus Q2 2024 Adj. EPS $1.80 Misses $1.83 Estimate, Sales $394.091M Beat $382.153M Estimate

B. Riley Securities analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $105 to $146.

B. Riley Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $146

Jones Trading analyst Justin Walsh maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $128 to $137.

Jones Trading Maintains Buy on Lantheus Holdings, Raises Price Target to $137

FTAI Aviation Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTAI#NYSE">FTAI</a>) and Applied Industrial Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIT#NYSE">AIT</a>) were among <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39797464/small-caps-are-having-a-moment-russell-2000-notches-best-5-day-rally-in-over-4-year">small-cap stocks</a> moving higher on Tuesday as the Russell 2000 Index had a fifth straight day of gains.
The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) gained 3.41% on Tuesday, ushering the index to a cumulative gain of over 9% across <a href="https://www.benzinga.com/topic/small-caps" target="_blank" rel="noreferrer noopener">the last five sessions.</a> This remarkable streak represents the Russell 2000's best five-day performance since June 2020.
FTAI Aviation, a provider of aircraft operations and engine maintenance, rose 5.63% to close at $107.42 on Tuesday, while Applied Industrial gained 4.63% to $210.59.
Also Read: <a href="https://www.benzinga.com/news/small-cap/23/12/36316131/russell-2000-rallies-to-16-month-highs-best-performing-small-cap-stocks-popping-over-80-in-decembe">Russell 2000 Rallies To 16-Month Highs: Best Performing Small-Cap Stocks Popping Over 80% In December</a>
FTAI Aviation accounts for 0.39% of the iShares Russell 2000 ETF, while Applied Industrial makes up 0.29% share, <a href="https://www.ishares.com/us/products/239710/ishares-russell-2000-etf">according </a>to iShares by BlackRock.
Individual stocks in the ETF that countered Tuesday&#8217;s small-cap advancement include Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>), which fell 3.97% to $118.30.
The rapid rise of small caps is attributed to the growing conviction that the Federal Reserve will lower interest rates at its September meeting. The Russell 2000 rally kicked off last week, driven by June inflation data coming in below expectations, sparking traders' speculation about rate cuts.
According to the CME Group's FedWatch Tool, fed futures now indicate a full 100% probability of an interest rate cut in nearly two months, marking the first reduction in borrowing costs since 2020. On Monday, Fed Chair&nbsp;Jerome Powell&nbsp;struck a dovish tone, acknowledging that recent inflation reports bolster confidence in returning to the 2% target, effectively hinting&nbsp;<a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39779256/powell-praises-latest-inflation-progress-hints-at-imminent-rate-cuts-warns-hes-ve" target="_blank" rel="noreferrer noopener">at forthcoming rate cuts.</a>
Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/03/37956811/russell-2000-vs-s-p-500-turning-tide-for-small-caps-risk-reward-trade-off-is-very-skewed">Russell 2000 Vs. S&amp;P 500: Turning Tide For Small Caps? &#8216;Risk-Reward Trade-Off Is Very Skewed&#8217;</a></li>
</ul>
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" target="_blank" rel="noreferrer noopener">Benzinga SmallCAP Conference</a>&nbsp;on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!
Image created using artificial intelligence via Midjourney.

Russell 2000 Marks Fifth Day Of Gains: What's Driving Surge In Small-Cap Stocks?

Lantheus Acquires Meilleur Technologies, Including The NAV-4694 ß Amyloid PET Imaging Agent For Alzheimer's Disease; Financial Terms Not Disclosed

These eleven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo <a href="https://www.benzinga.com//node/39727990" target="_blank" rel="noreferrer noopener">to industrialize solid-state batteries</a>.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized <a href="https://www.benzinga.com//node/39717130" target="_blank" rel="noreferrer noopener">Diagnostic Radiopharmaceuticals</a>.</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data.</li>
<li>Kymera Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYMR#NASDAQ">KYMR</a>) shares rose 37.38% after the company announced its intention to expand Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis to more rapidly progress towards pivotal studies following<a href="https://www.benzinga.com//node/39675035" target="_blank" rel="noreferrer noopener"> an interim review of safety and efficacy</a>.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) shares upped 35.68%.</li>
<li>Joby Aviation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) stock was up 29.10% after the company announced it successfully flew a hydrogen-electric air taxi demonstrator 523 miles, with <a href="https://www.benzinga.com//node/39733461" target="_blank" rel="noreferrer noopener">water as the only by-product</a>.</li>
<li>Crinetics Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>) shares grew 21.18%  after JP Morgan raised its <a href="https://www.benzinga.com/quote/crnx/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $47 to $54</a>.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) stock grew 19.75% after JP Morgan maintained an Overweight rating on the stock and raised its <a href="https://www.benzinga.com/quote/DYN/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $39 to $43</a>.</li>
<li>Summit Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock gained 17.24% in the last week.</li>
<li>Plug Power Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLUG#NASDAQ">PLUG</a>) stock upped 16.51% as EV-related stocks gained <a href="https://www.benzinga.com/economics/macro-economic-events/24/07/39728268/inflation-slows-more-expected-to-3-in-june-heightens-expectations-for-rate-cuts-t" target="_blank" rel="noreferrer noopener">following recent CPI Data</a>. The Department of Energy also announced a $1.7 billion to convert 11 shuttered or at-risk auto facilities to manufacture electric vehicles and their supply chain.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) stock rose 15.56%. Shares of Chinese stocks gained following an increase in China's June exports.</li>
</ol>
Also Read
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39763253/rivian-automotive-baidu-are-among-top-11-large-cap-stocks-that-shined-the-brightest-last-week-ju" target="_blank" rel="noreferrer noopener">Rivian Automotive &amp; Baidu Are Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 7-July 13): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39763431/netflix-delta-air-lines-and-hubspot-are-among-top-10-large-stocks-that-performed-worst-this-week" target="_blank" rel="noreferrer noopener">Netflix, Delta Air Lines And HubSpot Are Among Top 10 Large Stocks That Performed Worst This Week (July 7-July 13): Are The Others In Your Portfolio?</a></li>
</ul>
Photo Courtesy of QuantumScape

XPeng & QuantumScape Are Among Top 11 Mid Cap Stocks That Performed Well Last Week (July 7-July 13): Details

The Russell 2000 index of small caps, tracked by the iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>), recorded its best weekly performance since October 2023, surging over 6% and reaching its highest <a href="https://www.benzinga.com/topic/small-caps">level since January 2022.</a>
The rally was largely driven by Thursday&#8217;s session, where the Russell 2000 posted a remarkable 3.6% daily gain. This spike followed lower-than-expected June inflation data, which fueled speculation of potential interest rate cuts.
However, Quincy Krosby, chief global strategist for LPL Financial, advises caution, suggesting that Russell 2000&#8217;s rate cut message may be &#8220;clouded by Fed&#8217;s concerns over labor market.&#8221;
Krosby thinks a weaker labor market would still hurt the economically sensitive Russell 2000 index, and rate cuts may not necessarily shield it from a broader economic slowdown.
<h1 class="wp-block-heading">Chart of The Week: Small Caps Achieved Best-Performing Week In Over 8 Months</h1>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="488" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png" alt="" class="wp-image-434094" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1024x488.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-300x143.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-768x366.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21-1536x732.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/07/12145314/Screenshot-2024-07-12-alle-20.34.21.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Image: <a href="URL:&nbsp;http://www.benzinga.com/pro/register/?utm_source=BZprocontent071224&amp;t=be2bearmibe3na1">Benzinga Pro</a>
The Russell 2000&#8217;s impressive performance highlights a significant shift in market focus, with interest rate-sensitive small and mid-cap stocks benefiting as investors move away from mega-tech names and direct inflows into the broader market, Krosby highlighted.
The analyst indicated the Russell 2000 serves as a critical indicator for potential interest rate easing and broader economic conditions. Typically, the small- and mid-cap universe will sell off at any hint of a significant economic slowdown, despite their attractive valuations.
&#8220;Historically, the Russell 2000 lags the market for three months following the first rate cut as the Fed normally cuts rates due to concerns about the economy and specifically the labor market. Fed Chair Powell has made it clear, as he continues to invoke the Fed's maximum employment mandate, that the Fed would cut rates at a faster pace to help support the economy,&#8221; she said. 
If labor market conditions deteriorate, the Fed might initiate an easing cycle sooner than the scheduled Sept. 18 meeting, Krosby stated. The market prefers a rate cut driven by inflation easing within a robust economic backdrop.
<h1 class="wp-block-heading">This Week&#8217;s Top Performers In The Russell 2000</h1>
<ol>
<li>Morphic Holding, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORF#NASDAQ">MORF</a>): 75.16% (Health Care)</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>): 55.47% (Health Care)</li>
<li>IGM Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>): 54.22% (Health Care)</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>): 52.63% (Information Technology)</li>
<li>Methode Electronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NASDAQ">MEI</a>): 47.96% (Information Technology)</li>
<li>Solaris Oilfield Infrastructure, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOI#NYSE">SOI</a>): 46.87% (Energy)</li>
<li>Pulse Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLSE#NASDAQ">PLSE</a>): 45.98% (Health Care)</li>
<li>Ouster, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>): 44.21% (Information Technology)</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>): 42.65% (Consumer Discretionary)</li>
<li>Sunrun Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUN#NASDAQ">RUN</a>): 42.51% (Industrials)</li>
</ol>

Read Now:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/07/39750466/us-consumer-morale-dips-more-than-expected-in-july-sentiment-remains-stubbornly-subdued">US Consumer Morale Dips More Than Expected In July: Sentiment &#8216;Remains Stubbornly Subdued&#8217;</a></li>
</ul>
Photo: Shutterstock

Russell 2000 Index Notches Strongest Week Of Year, Hits 31-Month Highs: Outlook Is 'Clouded By Fed's Concerns Over Labor Market,' Analyst Warns

Shares of Conagra Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>) fell during Thursday's session after the company reported worse-than-expected fourth-quarter sales results and issued FY25 adjusted <a href="https://www.benzinga.com/news/earnings/24/07/39728345/conagra-falls-short-on-q4-revenue-amid-unfavorable-price-mix">EPS guidance below estimates</a>.
The company reported adjusted earnings per share of 61 cents, beating the analyst consensus estimate of 57 cents. Quarterly revenues of $2.905 billion missed the street view of $2.930 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Conagra Brands shares declined 3.9% to $27.70 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Kazia Therapeutics Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares surged 88.6% to $1.26. Kazia Therapeutics, on Wednesday, announced results from GBM-AGILE, a phase II/III study that included an evaluation of paxalisib versus standard of care for patients with glioblastoma.</li>
<li>Biodexa Pharmaceuticals Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares jumped 78.6% to $1.2698 after the company reported 12-month Phase 2 trial results for eRapa in treating Familial Adenomatous Polyposis.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) climbed 68.2% to $6.13 in response to a series of buy-sell transactions by UBS Group AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBS#NYSE">UBS</a>).</li>
<li>iSpecimen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) jumped 48% to $0.4241.</li>
<li>Renalytix Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) gained 35% to $0.4125 after the company announced a collaboration with the Steno Diabetes Center, Copenhagen, to advance translation of precision medicine solutions for patients with Diabetes and Chronic Kidney Disease.</li>
<li>Blue Star Foods Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSFC#NASDAQ">BSFC</a>) shares rose 33.6% to $2.2450 after declining around 5% on Wednesday.</li>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) gained 32.5% to $5.25. Cyngn announced the expansion of its dealer network to include Alta Equipment Group.</li>
<li>Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) shares rose 29.4% to $12.22 after the company reported better-than-expected fourth-quarter sales results.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) gained 25% to $6.76 after the company announced it entered into an agreement with PowerCo to industrialize solid-state batteries.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) jumped 18.2% to $8.63.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) rose 16.7% to $5.92. SoundHound AI recently announced that its ChatGPT-integrated voice assistant is now live and in production in Peugeot, Opel and Vauxhall vehicle brands in Europe.</li>
<li>LL Flooring Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LL#NYSE">LL</a>) jumped 15.4% to $0.7850.</li>
<li>Astrana Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) gained 11.2% to $42.47. Truist Securities analyst Jailendra Singh upgraded Astrana Health from Hold to Buy and raised the price target from $44 to $50.</li>
<li>IGM Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IGMS#NASDAQ">IGMS</a>) shares rose 10.8% to $7.76.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) climbed 10.8% to $3.60 after Rosenblatt initiated coverage on the stock with a Buy rating and announced a $5 price target.</li>
<li>OKYO Pharma Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKYO#NASDAQ">OKYO</a>) gained 10.2% to $1.3003 as the company announced plans to initiate neuropathic corneal pain trial for OK-101.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) shares rose 9.7% to $1.72 after the company announced it received a significant order valued at $260,000 to modernize the traffic systems in a major Mid-Atlantic county in the United States.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) shares gained 8.4% to $5.07 after surging 44% on Wednesday.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) rose 8.2% to $114.89. Leerink Partners maintained Lantheus with an Outperform and raised the price target from $106 to $127.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) rose 8% to $1,410.01 after the company announced a 10-for-1 stock split.</li>
<li>Virpax Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) rose 7.6% to $1.8307.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 6.6% to $318.49.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) dipped 28.1% to $5.32 after jumping 110% on Wednesday. Inspire Veterinary Partners announced the closing of $6 million public offering.</li>
<li>Cingulate Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CING#NASDAQ">CING</a>) fell 25% to $0.4862 after gaining 74% on Wednesday.</li>
<li>Crown LNG Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGBS#NASDAQ">CGBS</a>) dipped 18.6% to $2.5102.</li>
<li>Telesis Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) declined 18.2% to $3.5736.</li>
<li>Boqii Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BQ#NYSE">BQ</a>) dipped 17.6% to $0.4271.</li>
<li>TuanChe Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) shares fell 17.5% to $1.5996.</li>
<li>Clene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLNN#NASDAQ">CLNN</a>) fell 15.7% to $4.7350. Clene announced plans to submit briefing book to the U.S. FDA in connection with granted Type C interaction to obtain FDA feedback on potential pathway to accelerated approval for CNM-Au8 in ALS.</li>
<li>E2open Parent Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NASDAQ">ETWO</a>) declined 15.7% to $3.72 after the company reported worse-than-expected first-quarter sales results.</li>
<li>uniQure N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QURE#NASDAQ">QURE</a>) dipped 14.2% to $8.68. The company recently announced updated interim data including up to 24 months of follow-up data from 29 treated patients enrolled in the ongoing U.S. and European Phase I/II clinical trials of AMT-130 for the treatment of</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares fell 9.4% to $4.1191. Longeveron shares jumped over 58% on Wednesday after the company announced that the FDA granted Regenerative Medicine Advanced Therapy designation to Lomecel-B for the treatment of mild Alzheimer&#8217;s Disease.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) dipped 9% to $18.06.</li>
<li>Innovative Eyewear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCY#NASDAQ">LUCY</a>) fell 8% to $0.4210 after gaining over 20% on Wednesday.</li>
<li>BRC Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRCC#NYSE">BRCC</a>) fell 7.7% to $4.9850.</li>
<li>Delta Air Lines, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAL#NYSE">DAL</a>) fell 7.1% to $43.56 after the company posted downbeat second-quarter earnings and issued lower-than-expected third-quarter earnings outlook.</li>
<li>American Airlines Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAL#NASDAQ">AAL</a>) declined 6.2% to $10.45 in sympathy with Delta, which fell after reporting mixed quarterly earnings.</li>
<li>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) fell 5.5% to $44.58 in sympathy with Delta, which fell after reporting mixed quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) fell 5.4% to $58.18. Celestica is expected to release second quarter financial results on Wednesday, July 24.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/general/restaurants/24/07/39728857/jim-cramer-says-dont-panic-about-cava-calls-this-industrial-company-terrific">Jim Cramer Says &#8216;Don&#8217;t Panic&#8217; About Cava, Calls This Industrial Company &#8216;Terrific</a><a href="https://www.benzinga.com/general/restaurants/24/07/39728857/jim-cramer-says-dont-panic-about-cava-calls-this-industrial-company-terrific">&#8216;</a></li>
</ul>

Intraday Update

Trading Ideas

ASNS

ASTH

BDRX

BRCC

BSFC

CGBS

CING

CLNN

ETWO

ISPC

KZIA

LGVN

LUCY

MSTR

NAAS

OKYO

POOL

QURE

RBBN

RNLX

TBIO

TERN

VLCN

VRPX

Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Lantheus Holdings shares are trading higher after Leerink Partners maintained an Outperform rating on the stock and raised its price target from $106 to $127. Also, Truist Securities maintained a Buy rating on the stock and raised its price target from $96 to $141.

U.S. stocks were mostly higher, with the Dow Jones index gaining around 100 points on Thursday.
Shares of Methode Electronics, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MEI#NYSE">MEI</a>) rose sharply during Thursday's session after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/07/39728841/oem-supplier-methode-electronics-q4-earnings-revenue-beat-eps-miss-ceo-transition-and-more">fourth-quarter sales results</a>.
Methode Electronics reported a fourth-quarter fiscal 2024 net sales decline of 7.9% year-on-year to $277.30 million, beating the analyst consensus estimate of $264.04 million. Adjusted EPS loss of 23 cents missed the analyst consensus loss estimate of 20 cents, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Methode Electronics shares surged 29.4% to $12.22 on Thursday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 25% to $6.76 after the company announced it entered into an agreement with PowerCo to industrialize solid-state batteries.</li>
<li>Terns Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) gained 18.2% to $8.63.</li>
<li>SoundHound AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOUN#NASDAQ">SOUN</a>) shares gained 16.7% to $5.92. SoundHound AI recently announced that its ChatGPT-integrated voice assistant is now live and in production in Peugeot, Opel and Vauxhall vehicle brands in Europe.</li>
<li>Pacific Biosciences of California, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) rose 14% to $1.48.</li>
<li>Embecta Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EMBC#NASDAQ">EMBC</a>) gained 11.7% to $13.40.</li>
<li>Astrana Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) jumped 11.2% to $42.47. Truist Securities analyst Jailendra Singh upgraded Astrana Health from Hold to Buy and raised the price target from $44 to $50.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) gained 10.8% to $3.60 after Rosenblatt initiated coverage on the stock with a Buy rating and announced a $5 price target.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) rose 9.5% to $8.52.</li>
<li>Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APGE#NASDAQ">APGE</a>) climbed 9.2% to $46.08.</li>
<li>Joby Aviation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NASDAQ">JOBY</a>) gained 8.2% to $5.61. Joby Aviation said it has flown a first-of-its-kind hydrogen-electric air taxi demonstrator 523 miles, with water as the only by-product.</li>
<li>Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) surged 8.2% to $114.89. Leerink Partners maintained Lantheus with an Outperform and raised the price target from $106 to $127.</li>
<li>MicroStrategy Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) shares climbed 8% to $1,410.01 after the company announced a 10-for-1 stock split.</li>
<li>Unity Software Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) gained 7.4% to $16.51. Unity is expected to release second quarter financial results after the closing bell on Aug. 8.</li>
<li>Q2 Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTWO#NASDAQ">QTWO</a>) rose 6.8% to $64.81.</li>
<li>Enphase Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) climbed 6.8% to $113.99 after the company announced residential and commercial products that can help solar projects qualify for the &#8220;Domestic Content Bonus Credit.&#8221;</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) rose 6.6% to $318.49.</li>
<li>Installed Building Products, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBP#NYSE">IBP</a>) gained 6.4% to $223.75.</li>
<li>Yum China Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>) rose 5.5% to $32.17.</li>
<li>Chewy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) gained 4.6% to $26.57.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/07/39728116/how-to-earn-500-a-month-from-jpmorgan-chase-stock-ahead-of-q2-earnings-report">How To Earn $500 A Month From JPMorgan Chase Stock Ahead Of Q2 Earnings Report</a></li>
</ul>

CHWY

EMBC

ENPH

IOVA

PACB

QTWO

YUMC

Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-ratings/">analyst ratings page</a>.
<ul>
<li>Morgan Stanley cut the price target for Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) from $102 to $100. Morgan Stanley analyst Joseph Moore downgraded the stock from Overweight to Equal-Weight. Microchip Technology shares rose 3.9% to close at $95.98 on Wednesday. <a href="https://www.benzinga.com/quote/MCHP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities lifted the price target for Astrana Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTH#NASDAQ">ASTH</a>) from $44 to $50. Truist Securities analyst Jailendra Singh upgraded the stock from Hold to Buy. Astrana Health shares fell 0.4% to close at $38.20 on Wednesday. <a href="https://www.benzinga.com/quote/ASTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted the price target for Costco Wholesale Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) from $850 to $975. Baird analyst Peter Benedict maintained an Outperform rating. Costco shares fell 0.3% to close at $884.31 on Wednesday. <a href="https://www.benzinga.com/quote/COST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Wedbush increased CAVA Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) price target from $90 to $100. Wedbush analyst Nick Setyan maintained an Outperform rating. CAVA shares fell 5.5% to close at $85.30 on Wednesday. <a href="https://www.benzinga.com/quote/CAVA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Guggenheim boosted the price target for Dutch Bros Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BROS#NYSE">BROS</a>) from $30 to $36. Guggenheim analyst Gregory Francfort maintained a Neutral rating. Dutch Bros shares fell 4.3% to close at $39.46 on Wednesday. <a href="https://www.benzinga.com/quote/BROS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Keybanc cut Phreesia, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHR#NYSE">PHR</a>) price target from $27 to $25. Keybanc analyst Scott Schoenhaus maintained an Overweight. Phreesia shares fell 7% to close at $18.82 on Wednesday. <a href="https://www.benzinga.com/quote/PHR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler increased Kimberly-Clark Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) price target from $167 to $174. Piper Sandler analyst Korinne Wolfmeyer maintained an Overweight rating. Kimberly-Clark shares gained 1% to close at $140.79 on Wednesday. <a href="https://www.benzinga.com/quotBe/KM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners raised Lantheus Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) price target from $106 to $127. Leerink Partners maintained an Outperform rating. Lantheus shares jumped 36.7% to close at $106.18 on Wednesday. <a href="https://www.benzinga.com/quote/LNTH/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Baird boosted Sprouts TaskUs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TASK#NASDAQ">TASK</a>) price target from $14 to $16. Baird analyst David Koning maintained an Outperform rating. TaskUs shares gained 3.1% to close at $14.54 on Wednesday. <a href="https://www.benzinga.com/quote/TASK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised Annovis Bio, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) price target from $23 to $30. HC Wainwright &amp; Co. analyst Raghuram Selvaraju maintained a Buy rating. Annovis Bio shares fell 17.1% to close at $12.08 on Wednesday. <a href="https://www.benzinga.com/quote/ANVS/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39726449/top-4-real-estate-stocks-that-could-lead-to-your-biggest-gains-in-q3">Top 4 Real Estate Stocks That Could Lead To Your Biggest Gains In Q3</a></li>
</ul>

ANVS

BROS

CAVA

COST

MCHP

TASK

Costco To Rally More Than 10%? Here Are 10 Top Analyst Forecasts For Thursday

Truist Securities analyst Richard Newitter maintains Lantheus Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) with a Buy and raises the price target from $96 to $141.

Truist Securities Maintains Buy on Lantheus Holdings, Raises Price Target to $141

ClearBridge Small Cap Value Strategy Q2 2024 Commentary

Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)

Novartis expands U.S. radiopharma production amid rising competition

An update from Lantheus ( ($LNTH) ) is now available. Lantheus Holdings, Inc., a leader in radiopharmaceuticals, has announced the appointment of J...

Lantheus Bolsters Board with Expert Finance Executive

Perspective gets FDA fast track status for radiopharmaceutical VMT101

Perspective gets FDA fast track status for radiopharmaceutical VMT01

In a report released today, Richard Newitter from Truist Financial assigned a Buy rating to Lantheus (LNTH – Research Report). The company's shares...

Truist Financial Issues a Buy Rating on Lantheus (LNTH)

TD Cowen analyst Tara Bancroft maintained a Buy rating on Lantheus (LNTH – Research Report) today and set a price target of $145.00. The company's ...

TD Cowen Remains a Buy on Lantheus (LNTH)

JonesTrading analyst Justin Walsh has reiterated their bullish stance on LNTH stock, giving a Buy rating today. Justin Walsh has given his Buy rati...

Buy Rating Reaffirmed for Lantheus Holdings Amid Promising PNT2002 Trial Results

Janus Henderson Triton Fund Q2 2024 Commentary

ACHC

ALGT

ALIT

ASTS

ASTSW

ATNM

BAYRY

BHVN

BLKB

CASI

CASY

CATX

CFCV

CLRB

CORT

CRTO

FWRD

GEHC

GKOS

GMED

GOOG

GOOGL

HLMN

INFR

LPLA

LRGE

MUSA

NATL

NCRRP

NCSYF

NICE

NVDA

NVSEF

OSIS

PRIM

QDEL

RKLIF

SKYW

SRRK

SSNC

TCBX

TLPPF

TSLA

VBTX

YLDE

Management

Press Releases

Lantheus Appoints Jamie Spaeth as Chief People Officer

Health Care

Lantheus Welcomes CMS' Proposed CY25 Rule for Improved Payment for Specialized Diagnostic Radiopharmaceuticals to Support Patient Access

Lantheus Acquires NAV-4694, a Next-Generation ß Amyloid PET Imaging Agent for Alzheimer's Disease

Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time

Lantheus Reports Second Quarter 2024 Financial Results

Lantheus to Present Additional Clinical Data from Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Lantheus to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

Lantheus Appoints Julie Eastland as New Board Member

Lantheus Presents Results from the Primary Analysis of Phase 3 Pivotal SPLASH Trial in PSMA-Positive Metastatic Castration-Resistant Prostate Cancer During ESMO Congress 2024

Opinion

Cancer Research Sees Major Boost as New Breakthroughs Emerge from Key Oncology Players

DVAX

ONCY

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Lantheus Holdings

Lantheus Holdings (LNTH) Forecast

Lantheus Holdings (NASDAQ:LNTH) Stock, Quote.Headers.trade-ideas